Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 124Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Head and Neck Neoplasms 34Breast Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

pembrolizumab 1Vincristine 1Vinblastine 1Procarbazine 1Prednisone 1Methotrexate 1Mercaptopurine 1Magnetic Resonance Imaging 1Etoposide 1Drug Therapy 1Doxorubicin 1Dexamethasone 1Daunorubicin 1Cytarabine 1Cyclophosphamide 1Caspofungin 1BAY 1895344 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ataxia Telangiectasia × pembrolizumab × Clear all
NCT04095273 2024-04-02

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Bayer

Phase 1 Completed
56 enrolled

Ataxia Telangiectasia, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡